Rydex Health Care H holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
Rydex Health Care Fund Class H RYHAX
- NAV / 1-Day Return 115.18 / −0.18 %
- Total Assets 18.3M
-
Adj. Expense Ratio
1.640%
- Expense Ratio 1.640%
- Distribution Fee Level High
- Share Class Type No Load
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment 2,500
- Status Open
- TTM Yield 0.00
- Turnover 236%
USD | NAV as of Jun 17, 2026 | 1-Day Return as of Jun 17, 2026, 12:10 AM GMT+0
Morningstar’s Analysis RYHAX
Will RYHAX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the RYHAX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of RYHAX’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 24.3
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 4.16 | 855,649 | Healthcare |
Johnson & Johnson | 3.37 | 693,567 | Healthcare |
AbbVie Inc | 2.78 | 573,359 | Healthcare |
Merck & Co Inc | 2.43 | 499,744 | Healthcare |
Thermo Fisher Scientific Inc | 2.06 | 423,543 | Healthcare |
UnitedHealth Group Inc | 2.04 | 419,492 | Healthcare |
Gilead Sciences Inc | 1.97 | 405,125 | Healthcare |
Amgen Inc | 1.96 | 404,444 | Healthcare |
Abbott Laboratories | 1.79 | 369,215 | Healthcare |
Intuitive Surgical Inc | 1.79 | 369,089 | Healthcare |
United States